Balance Sheet United Therapeutics Corporation

Stocks

UTHR

US91307C1027

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 10:55:04 16/07/2026 pm IST			5-day change	1st Jan Change
529.60 ^USD	-0.41%		-3.95%	+8.91%

15/07	United Therapeutics Insider Sold Shares Worth $5,091,949, According to a Recent SEC Filing	MT
14/07	United Therapeutics Insider Sold Shares Worth $5,173,660, According to a Recent SEC Filing	MT

a339efc.Jo5jHF2RNJQEM_tJECMd8qqxZ6lCx9tuD5BT0D03hKI.TMVVfgn_RcAxaY05Q0R0y-aBINA1j6g4PqVmplpAtpdLowZKLf95-lwFzw

Published financial data: UNITED THERAPEUTICS CORPORATION

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2021	2022	2023	2024	2025
Revenues	168.55Cr	193.63Cr	232.75Cr	287.74Cr	318.27Cr
Total Revenues	168.55Cr	193.63Cr	232.75Cr	287.74Cr	318.27Cr
Cost of Goods Sold, Total	12Cr	15Cr	26Cr	31Cr	38Cr
Gross Profit	156.3Cr	178.47Cr	207Cr	256.77Cr	279.83Cr
Selling General & Admin Expenses, Total	47Cr	47Cr	48Cr	64Cr	73Cr
R&D Expenses	41Cr	32Cr	41Cr	48Cr	55Cr
Other Operating Expenses, Total	88Cr	80Cr	88Cr	112.14Cr	128.12Cr
Operating Income	69Cr	99Cr	118.6Cr	144.63Cr	151.71Cr
Interest Expense, Total	-1.86Cr	-3.24Cr	-5.93Cr	-4.29Cr	-1.95Cr
Interest And Investment Income	1.67Cr	4.52Cr	16Cr	20Cr	19Cr
Net Interest Expenses	-19L	1.28Cr	10Cr	16Cr	17Cr
Other Non Operating Income (Expenses)	-70L	-7.42Cr	-2.73Cr	-14L	60L
EBT, Excl. Unusual Items	68Cr	93Cr	126.21Cr	160.11Cr	169.56Cr
Merger & Related Restructuring Charges	-	-	-	-	-
Gain (Loss) On Sale Of Investments	4.85Cr	3.42Cr	1.58Cr	90L	4.3Cr
Asset Writedown	-13Cr	-1.12Cr	-36L	-	-2.17Cr
Legal Settlements	-	-	-	-7.11Cr	-30L
Other Unusual Items	-	-	-	-	-
EBT, Incl. Unusual Items	59Cr	95Cr	127.43Cr	153.9Cr	171.39Cr
Income Tax Expense	12Cr	22Cr	29Cr	34Cr	38Cr
Earnings From Continuing Operations	48Cr	73Cr	98Cr	119.51Cr	133.47Cr
Net Income to Company	48Cr	73Cr	98Cr	119.51Cr	133.47Cr
Net Income - (IS)	48Cr	73Cr	98Cr	119.51Cr	133.47Cr
Net Income to Common Incl Extra Items	48Cr	73Cr	98Cr	119.51Cr	133.47Cr
Net Income to Common Excl. Extra Items	48Cr	73Cr	98Cr	119.51Cr	133.47Cr
Per Share Items
Net EPS - Basic	10.6	15.98	21.04	26.44	30.13
Basic EPS - Continuing Operations	10.6	15.98	21.04	26.44	30.13
Basic Weighted Average Shares Outstanding	4.49Cr	4.55Cr	4.68Cr	4.52Cr	4.43Cr
Net EPS - Diluted	10.06	15	19.81	24.64	27.86
Diluted EPS - Continuing Operations	10.06	15	19.81	24.64	27.86
Diluted Weighted Average Shares Outstanding	4.73Cr	4.85Cr	4.97Cr	4.85Cr	4.79Cr
Normalized Basic EPS	9.44	12.74	16.85	22.14	23.92
Normalized Diluted EPS	8.96	11.95	15.87	20.63	22.12
American Depositary Receipts Ratio (ADR)	0.05	0.05	0.05	0.05	0.05
Supplemental Items
EBITDA	74Cr	104.03Cr	123.92Cr	151.88Cr	160.27Cr
EBITA	69Cr	99Cr	118.63Cr	144.72Cr	151.8Cr
EBIT	69Cr	99Cr	118.6Cr	144.63Cr	151.71Cr
EBITDAR	74Cr	104.51Cr	124.49Cr	152.64Cr	161.16Cr
Total Revenues (As Reported)	168.55Cr	-	-	-	-
Effective Tax Rate - (Ratio)	19.89	23.49	22.72	22.35	22.12
Current Domestic Taxes	14Cr	27Cr	35Cr	41Cr	28Cr
Current Foreign Taxes	-	-	-	-	12L
Total Current Taxes	14Cr	27Cr	35Cr	41Cr	28Cr
Deferred Domestic Taxes	-1.88Cr	-5.08Cr	-6.44Cr	-6.41Cr	9.82Cr
Deferred Foreign Taxes	-	-	-	-	-5L
Total Deferred Taxes	-1.88Cr	-5.08Cr	-6.44Cr	-6.41Cr	9.77Cr
Normalized Net Income	42Cr	58Cr	79Cr	100.07Cr	105.98Cr
Interest on Long-Term Debt	1.86Cr	3.24Cr	5.93Cr	4.29Cr	1.95Cr
Non-Cash Pension Expense	16L	19L	-35L	-34L	1L
Supplemental Operating Expense Items
Research And Development Expense From Footnotes	54Cr	32Cr	41Cr	48Cr	55Cr
Net Rental Expense, Total	36L	48L	57L	76L	89L
Imputed Operating Lease Interest Expense	7L	15.25L	35.28L	50.23L	79.41L
Imputed Operating Lease Depreciation	29.38L	32.75L	21.72L	25.77L	10L
Stock-Based Comp., COGS (Total)	58L	49L	24L	54L	39L
Stock-Based Comp., R&D Exp. (Total)	2.44Cr	2.38Cr	1.56Cr	2.91Cr	3.23Cr
Stock-Based Comp., SG&A Exp. (Total)	11Cr	7.81Cr	2.11Cr	11Cr	11Cr
Total Stock-Based Compensation	14Cr	11Cr	3.91Cr	14Cr	15Cr

Fiscal Period: December	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	89Cr	96Cr	120.77Cr	169.72Cr	155.71Cr
Short Term Investments	103.59Cr	187.75Cr	178.64Cr	156.98Cr	136.32Cr
Total Cash And Short Term Investments	193.07Cr	283.87Cr	299.41Cr	326.7Cr	292.03Cr
Accounts Receivable, Total	20Cr	22Cr	28Cr	28Cr	35Cr
Other Receivables	-	7Cr	2.1Cr	-	-
Total Receivables	20Cr	29Cr	30Cr	28Cr	35Cr
Inventory	9.38Cr	10Cr	11Cr	16Cr	18Cr
Other Current Assets, Total	10Cr	15Cr	15Cr	17Cr	25Cr
Total Current Assets	232.36Cr	338.03Cr	355.1Cr	387.39Cr	370.25Cr
Gross Property Plant And Equipment	112.33Cr	124.42Cr	147.36Cr	171.36Cr	229.75Cr
Accumulated Depreciation	-34Cr	-38Cr	-43Cr	-49Cr	-57Cr
Net Property Plant And Equipment	78Cr	86Cr	104.54Cr	122.24Cr	172.97Cr
Long-term Investments	168.1Cr	134.47Cr	193.83Cr	153.43Cr	183.05Cr
Goodwill	2.8Cr	2.8Cr	3.37Cr	3.23Cr	3.23Cr
Other Intangibles, Total	1.66Cr	1.65Cr	8.05Cr	7.96Cr	8.42Cr
Deferred Tax Assets Long-Term	26Cr	33Cr	39Cr	46Cr	36Cr
Deferred Charges Long-Term	69L	1.05Cr	-	-	-
Other Long-Term Assets, Total	7.02Cr	7.53Cr	12Cr	16Cr	14Cr
Total Assets	516.91Cr	604.45Cr	716.7Cr	736.4Cr	788Cr
Liabilities
Accounts Payable, Total	38L	41L	56L	60L	71L
Accrued Expenses, Total	29Cr	33Cr	36Cr	38Cr	51Cr
Current Portion of Long-Term Debt	-	-	40Cr	30Cr	-
Current Portion of Leases	31L	39L	47L	61L	73L
Other Current Liabilities	71L	91L	3.58Cr	4.57Cr	3.93Cr
Total Current Liabilities	31Cr	34Cr	80Cr	74Cr	56Cr
Long-Term Debt	80Cr	80Cr	30Cr	-	-
Long-Term Leases	1.58Cr	2.78Cr	2.81Cr	3.25Cr	3.03Cr
Pension & Other Post Retirement Benefits	4.89Cr	3.2Cr	1.83Cr	2.13Cr	2.88Cr
Other Non Current Liabilities	4.01Cr	4.48Cr	3.14Cr	13Cr	16Cr
Total Liabilities	121.02Cr	124.78Cr	118.22Cr	92Cr	78Cr
Common Stock, Total	7L	7L	7L	8L	8L
Additional Paid In Capital	224.54Cr	238.84Cr	254.9Cr	269.89Cr	279.8Cr
Retained Earnings	431.5Cr	504.23Cr	602.71Cr	722.22Cr	855.69Cr
Treasury Stock	-257.92Cr	-257.92Cr	-257.92Cr	-347.45Cr	-426.04Cr
Comprehensive Income and Other	-2.3Cr	-5.55Cr	-1.28Cr	-34L	9L
Total Common Equity	395.89Cr	479.67Cr	598.48Cr	644.4Cr	709.62Cr
Total Equity	395.89Cr	479.67Cr	598.48Cr	644.4Cr	709.62Cr
Total Liabilities And Equity	516.91Cr	604.45Cr	716.7Cr	736.4Cr	788Cr
Supplemental Items
ECS Total Shares Outstanding on Filing Date	4.51Cr	4.63Cr	4.71Cr	4.49Cr	4.38Cr
ECS Total Common Shares Outstanding	4.51Cr	4.6Cr	4.7Cr	4.48Cr	4.36Cr
Book Value / Share	87.77	104.2	127.23	143.74	162.6
Tangible Book Value	391.43Cr	475.22Cr	587.06Cr	633.21Cr	697.97Cr
Tangible Book Value Per Share	86.78	103.24	124.8	141.24	159.93
Total Debt	82Cr	83Cr	73Cr	34Cr	3.76Cr
Net Debt	-276.17Cr	-332.32Cr	-417.11Cr	-440.37Cr	-465.94Cr
Debt Equivalent of Unfunded Proj. Benefit Obligation	6.71Cr	5.15Cr	4.88Cr	5.21Cr	5.48Cr
Debt Equivalent Oper. Leases	2.88Cr	3.84Cr	4.56Cr	6.08Cr	7.12Cr
Account Code - Inventory Valuation	5	5	5	5	5
Inventories - Raw Materials, Total	1.76Cr	1.8Cr	2.17Cr	2.86Cr	3.06Cr
Inventories - Work In Process, Total	3.19Cr	3.33Cr	3.44Cr	3.43Cr	3.53Cr
Inventories - Finished Goods, Total	4.43Cr	5.07Cr	5.57Cr	9.5Cr	12Cr
Land - (BS)	13Cr	14Cr	15Cr	18Cr	27Cr
Buildings, Total	61Cr	64Cr	69Cr	86Cr	94Cr
Machinery, Total	32Cr	35Cr	38Cr	45Cr	49Cr
Full Time Employees	965	985	1.17T	1.3T	1.4T

Fiscal Period: December	2021	2022	2023	2024	2025
Net Income	48Cr	73Cr	98Cr	119.51Cr	133.47Cr
Depreciation & Amortization - CF	4.98Cr	5.12Cr	5.29Cr	7.16Cr	8.47Cr
Amortization of Goodwill and Intangible Assets - (CF)	1L	1L	3L	9L	9L
Depreciation & Amortization, Total	4.99Cr	5.13Cr	5.32Cr	7.25Cr	8.56Cr
(Gain) Loss on Sale of Investments - (CF)	-9.03Cr	-54L	-	-	-
Asset Writedown & Restructuring Costs	13Cr	1.12Cr	36L	-	2.17Cr
Stock-Based Compensation (CF)	14Cr	11Cr	3.91Cr	14Cr	15Cr
Tax Benefit from Stock Options	-	-	-	-	-
Other Operating Activities, Total	6.59Cr	5.25Cr	-49L	-2.43Cr	7.8Cr
Change In Accounts Receivable	-4.13Cr	-2.17Cr	-5.85Cr	-4L	-7.09Cr
Change In Inventories	-75L	-1.34Cr	-1.36Cr	-4.69Cr	-5.26Cr
Change In Accounts Payable	-1.25Cr	4.45Cr	5.71Cr	4.27Cr	9.79Cr
Change in Other Net Operating Assets	-11Cr	-15Cr	-8.28Cr	-5.56Cr	-8.09Cr
Cash from Operations	60Cr	80Cr	98Cr	132.71Cr	156.12Cr
Capital Expenditure	-12Cr	-14Cr	-23Cr	-25Cr	-52Cr
Sale of Property, Plant, and Equipment	-	-	-	-	-
Cash Acquisitions	-	-	-8.92Cr	-	-
Divestitures	-	-	-	-	-
Sale (Purchase) of Intangible assets	-	-	-	-	-55L
Investment in Marketable and Equity Securities, Total	-37Cr	-68Cr	-38Cr	69Cr	-1.49Cr
Other Investing Activities, Total	-	35L	-2.3Cr	-2.85Cr	-1.04Cr
Cash from Investing	-49Cr	-81Cr	-72Cr	42Cr	-55Cr
Long-Term Debt Issued, Total	-	80Cr	-	-	20Cr
Total Debt Issued	-	80Cr	-	-	20Cr
Long-Term Debt Repaid, Total	-	-80Cr	-10Cr	-40Cr	-50Cr
Total Debt Repaid	-	-80Cr	-10Cr	-40Cr	-50Cr
Issuance of Common Stock	5.56Cr	9.43Cr	10Cr	16Cr	18Cr
Repurchase of Common Stock	-1.08Cr	-1.14Cr	-1.38Cr	-101.22Cr	-102.16Cr
Other Financing Activities, Total	-	-75L	-27L	-27L	-1.15Cr
Cash from Financing	4.48Cr	7.54Cr	-1.19Cr	-125.48Cr	-115Cr
Foreign Exchange Rate Adjustments	-	-	-	-	-
Net Change in Cash	16Cr	6.64Cr	25Cr	49Cr	-14Cr
Supplemental Items
Cash Interest Paid	1.62Cr	2.91Cr	5.6Cr	4.02Cr	1.35Cr
Cash Income Tax Paid (Refund)	15Cr	28Cr	33Cr	40Cr	31Cr
Levered Free Cash Flow	40Cr	50Cr	61Cr	82Cr	58Cr
Unlevered Free Cash Flow	42Cr	52Cr	64Cr	85Cr	60Cr
Change In Net Working Capital	8.17Cr	11Cr	-4.12Cr	2.24Cr	6.01Cr
Net Debt Issued / Repaid	-	0	-10Cr	-40Cr	-30Cr

Fiscal Period: December	2021	2022	2023	2024	2025
Profitability
Return on Assets	8.78	11.02	11.22	12.44	12.44
Return on Total Capital	9.57	11.9	12.04	13.42	13.65
Return On Equity %	12.94	16.61	18.27	19.23	19.71
Return on Common Equity	12.94	16.61	18.27	19.23	19.71
Margin Analysis
Gross Profit Margin %	92.73	92.17	88.94	89.24	87.92
SG&A Margin	27.65	24.42	20.45	22.26	22.97
EBITDA Margin %	43.71	53.73	53.24	52.78	50.36
EBITA Margin %	40.76	51.08	50.97	50.3	47.7
EBIT Margin %	40.75	51.08	50.96	50.26	47.67
Income From Continuing Operations Margin %	28.23	37.56	42.31	41.53	41.94
Net Income Margin %	28.23	37.56	42.31	41.53	41.94
Net Avail. For Common Margin %	28.23	37.56	42.31	41.53	41.94
Normalized Net Income Margin	25.14	29.94	33.89	34.78	33.3
Levered Free Cash Flow Margin	23.94	25.95	26.09	28.66	18.32
Unlevered Free Cash Flow Margin	24.63	26.99	27.68	29.59	18.71
Asset Turnover
Asset Turnover	0.34	0.35	0.35	0.4	0.42
Fixed Assets Turnover	2.23	2.36	2.44	2.54	2.16
Receivables Turnover (Average Receivables)	9.47	9.24	9.32	10.31	10.11
Inventory Turnover (Average Inventory)	1.36	1.55	2.41	2.3	2.25
Short Term Liquidity
Current Ratio	7.61	9.85	4.41	5.25	6.6
Quick Ratio	6.97	9.12	4.09	4.8	5.83
Operating Cash Flow to Current Liabilities	1.96	2.34	1.22	1.8	2.78
Days Sales Outstanding (Average Receivables)	38.56	39.5	39.15	35.5	36.1
Days Outstanding Inventory (Average Inventory)	268.61	235.71	151.53	159.36	161.9
Average Days Payable Outstanding	11.11	9.02	6.62	5.97	5.84
Cash Conversion Cycle (Average Days)	296.06	266.19	184.06	188.9	192.15
Long Term Solvency
Total Debt/Equity	20.68	17.34	12.24	5.25	0.53
Total Debt / Total Capital	17.14	14.78	10.91	4.99	0.53
LT Debt/Equity	20.61	17.26	5.48	0.5	0.43
Long-Term Debt / Total Capital	17.07	14.71	4.88	0.48	0.42
Total Liabilities / Total Assets	23.41	20.64	16.5	12.49	9.95
EBIT / Interest Expense	36.93	30.52	20	33.71	77.8
EBITDA / Interest Expense	39.81	32.26	20.99	35.58	82.65
(EBITDA - Capex) / Interest Expense	33.31	27.97	17.11	29.83	55.95
Total Debt / EBITDA	1.11	0.8	0.59	0.22	0.02
Net Debt / EBITDA	-3.73	-3.18	-3.35	-2.89	-2.89
Total Debt / (EBITDA - Capex)	1.32	0.92	0.72	0.26	0.03
Net Debt / (EBITDA - Capex)	-4.46	-3.67	-4.11	-3.44	-4.27
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	13.63	14.88	20.2	23.63	10.61
Gross Profit, 1 Yr. Growth %	13.66	14.18	15.99	24.04	8.98
EBITDA, 1 Yr. Growth %	13.35	41.19	19.12	22.56	5.16
EBITA, 1 Yr. Growth %	14.44	43.97	19.94	21.99	4.52
EBIT, 1 Yr. Growth %	14.46	43.98	19.92	21.95	4.52
Earnings From Cont. Operations, 1 Yr. Growth %	-7.58	52.86	35.4	21.35	11.68
Net Income, 1 Yr. Growth %	-7.58	52.86	35.4	21.35	11.68
Normalized Net Income, 1 Yr. Growth %	11.79	36.81	36.06	26.86	5.9
Diluted EPS Before Extra, 1 Yr. Growth %	-12.82	49.11	32.07	24.38	13.07
Accounts Receivable, 1 Yr. Growth %	26.24	10.92	26.54	0.14	25.38
Inventory, 1 Yr. Growth %	8.44	8.74	9.61	41.23	15.96
Net Property, Plant and Equip., 1 Yr. Growth %	6.74	10.32	21.35	16.93	41.5
Total Assets, 1 Yr. Growth %	12.01	16.94	18.57	2.75	7.01
Tangible Book Value, 1 Yr. Growth %	20.92	21.41	23.53	7.86	10.23
Common Equity, 1 Yr. Growth %	16.6	21.16	24.77	7.67	10.12
Cash From Operations, 1 Yr. Growth %	-20.84	34.15	21.87	35.7	17.64
Capital Expenditures, 1 Yr. Growth %	103.71	14.9	65.99	6.99	111.16
Levered Free Cash Flow, 1 Yr. Growth %	-39.9	23.53	19.95	34.76	-30.08
Unlevered Free Cash Flow, 1 Yr. Growth %	-39.49	24.94	22.38	31.2	-30.84
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	7.86	14.25	17.51	21.9	16.94
Gross Profit, 2 Yr. CAGR %	8.36	13.92	15.08	19.95	16.27
EBITDA, 2 Yr. CAGR %	136.53	26.87	29.69	20.83	13.61
EBITA, 2 Yr. CAGR %	96.79	28.76	31.41	20.96	13.01
EBIT, 2 Yr. CAGR %	96.66	28.77	31.4	20.93	12.99
Earnings From Cont. Operations, 2 Yr. CAGR %	113.38	18.86	43.87	28.19	16.42
Net Income, 2 Yr. CAGR %	113.38	18.86	43.87	28.19	16.42
Normalized Net Income, 2 Yr. CAGR %	107.55	21.54	31.6	28.91	15.35
Diluted EPS Before Extra, 2 Yr. CAGR %	105.16	14.01	40.33	28.17	18.59
Accounts Receivable, 2 Yr. CAGR %	14.56	18.33	18.47	12.57	12.06
Inventory, 2 Yr. CAGR %	0.21	8.59	9.17	24.42	27.97
Net Property, Plant and Equip., 2 Yr. CAGR %	2.83	8.52	15.7	19.12	28.63
Total Assets, 2 Yr. CAGR %	14.93	14.44	17.75	10.38	4.86
Tangible Book Value, 2 Yr. CAGR %	22.18	21.16	22.47	15.43	9.04
Common Equity, 2 Yr. CAGR %	19.33	18.86	22.95	15.91	8.89
Cash From Operations, 2 Yr. CAGR %	70.16	3.05	27.86	28.6	26.35
Capital Expenditures, 2 Yr. CAGR %	20.14	52.99	38.1	33.26	50.3
Levered Free Cash Flow, 2 Yr. CAGR %	35.1	-13.35	22.2	27.63	-2.5
Unlevered Free Cash Flow, 2 Yr. CAGR %	46.49	-12.58	24.11	27.17	-4.33
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	1.17	10.15	16.2	19.52	18.02
Gross Profit, 3 Yr. CAGR %	3.03	10.27	14.6	17.99	16.17
EBITDA, 3 Yr. CAGR %	-4.21	99.15	24.23	27.27	15.5
EBITA, 3 Yr. CAGR %	-5.05	77.32	25.75	28.19	15.35
EBIT, 3 Yr. CAGR %	-5.05	77.25	25.75	28.17	15.33
Earnings From Cont. Operations, 3 Yr. CAGR %	-6.88	90.93	24.14	35.93	22.43
Net Income, 3 Yr. CAGR %	-6.88	90.93	24.14	35.93	22.43
Normalized Net Income, 3 Yr. CAGR %	-5.85	80.63	26.2	30	20.73
Diluted EPS Before Extra, 3 Yr. CAGR %	-9.09	84.46	19.74	34.8	22.92
Accounts Receivable, 3 Yr. CAGR %	4.19	13.33	21.01	12.02	16.69
Inventory, 3 Yr. CAGR %	-2.44	2.98	8.93	18.96	21.53
Net Property, Plant and Equip., 3 Yr. CAGR %	3.73	5.27	12.63	16.11	26.16
Total Assets, 3 Yr. CAGR %	14.97	15.59	15.8	12.52	9.24
Tangible Book Value, 3 Yr. CAGR %	14.35	21.92	21.95	17.39	13.67
Common Equity, 3 Yr. CAGR %	12.39	19.93	20.8	17.63	13.94
Cash From Operations, 3 Yr. CAGR %	-8.4	57.19	8.98	30.42	24.84
Capital Expenditures, 3 Yr. CAGR %	-13.15	18.36	57.21	26.84	55.36
Levered Free Cash Flow, 3 Yr. CAGR %	8.24	31.46	-3.18	26.58	4.83
Unlevered Free Cash Flow, 3 Yr. CAGR %	8.29	39.26	-1.96	26.74	4.18
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	1.06	2.33	7.41	14.71	16.5
Gross Profit, 5 Yr. CAGR %	0.48	1.96	7.69	14.04	15.27
EBITDA, 5 Yr. CAGR %	-7.55	-0.25	8.13	63.07	19.92
EBITA, 5 Yr. CAGR %	-8.3	-0.67	8.13	52.17	20.54
EBIT, 5 Yr. CAGR %	-8.3	-0.66	8.13	52.11	20.53
Earnings From Cont. Operations, 5 Yr. CAGR %	-7.79	11.72	10.82	62.8	20.99
Net Income, 5 Yr. CAGR %	-7.79	11.72	10.82	62.8	20.99
Normalized Net Income, 5 Yr. CAGR %	-8.55	-2.06	9.21	59.03	21.98
Diluted EPS Before Extra, 5 Yr. CAGR %	-7.98	10.01	8.15	59.46	19.28
Accounts Receivable, 5 Yr. CAGR %	-1.52	-5.8	9.68	13.03	17.34
Inventory, 5 Yr. CAGR %	-1.27	-1.12	2.05	11.07	16.18
Net Property, Plant and Equip., 5 Yr. CAGR %	9.8	9.56	8.36	10.6	18.78
Total Assets, 5 Yr. CAGR %	17.32	15.99	16.08	13.48	11.29
Tangible Book Value, 5 Yr. CAGR %	16.58	18.24	17.53	19.28	16.61
Common Equity, 5 Yr. CAGR %	16.42	17.94	16.5	18.31	15.89
Cash From Operations, 5 Yr. CAGR %	-1.45	11.1	4.67	45.06	15.62
Capital Expenditures, 5 Yr. CAGR %	26.02	9.97	4.55	24.11	54.41
Levered Free Cash Flow, 5 Yr. CAGR %	-4.57	-4.04	13.79	30.12	-2.71
Unlevered Free Cash Flow, 5 Yr. CAGR %	-4.12	-3.45	14.53	34.49	-2.73